Imetelstat
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 171 publications
Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.
Journal: Haematologica
Published: June 22, 2026
Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition.
Journal: Seminars in hematology
Published: May 11, 2026
Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting.
Journal: Journal of hematology & oncology
Published: April 19, 2026
Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis.
Journal: Frontiers in oncology
Published: April 11, 2026
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.
Journal: American journal of hematology
Published: April 01, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.
Journal: Blood cancer journal
Published: February 03, 2026
Designing Telomerase Inhibitors for Cancer Therapy: Mechanistic Insights, Medicinal Chemistry Strategies, Challenges, and Future Directions.
Journal: Archiv der Pharmazie
Published: January 18, 2026
Updates in low/intermediate-risk MDS.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 24, 2025
Last Updated: 09/26/2026